| Cancer |
CancerType |
Treatment |
Signature |
SearchID |
Experimental |
PMID |
Details |
Boxplot |
Network |
Correlation |
Survival |
| Head and Neck Cancer | HNSC | Cetuximab | CD137 | TNFRSF9 | clinical trial Phase II | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | HLA-DR | NA | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | CD86 | CD86 | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | TAP-1 | TAP1 | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | TAP-2 | TAP2 | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | LMP-2 | NA | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | Bcl-XL | BCL2L1 | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | urelumab | Bcl-XL | BCL2L1 | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | Bcl-XL | BCL2L1 | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | Bcl-2 | BCL2 | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | urelumab | Bcl-2 | BCL2 | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | Bcl-2 | BCL2 | cell lines | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | CD137 | TNFRSF9 | clinical trial Phase IB | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | granzyme B | GZMB | clinical trial Phase IB | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | Ki67 | MKI67 | clinical trial Phase IB | 27496866 | Details |  |  |  |  |
| Head and Neck Cancer | HNSC | Cetuximab | NKp46 | NCR1 | clinical trial Phase IB | 27496866 | Details |  |  |  |  |